# A Phase II Study of AK146D1 in Combination With AK112 in Advanced Non-Small Cell Lung Cancer

> **NCT07669779** · PHASE2 · RECRUITING · sponsor: **Akeso** · enrollment: 348 (estimated)

## Conditions studied

- Advanced Non Small Cell Lung Cancer (NSCLC)

## Interventions

- **DRUG:** AK146D1 for injection
- **DRUG:** AK112 Injection
- **DRUG:** Platinum chemotherapy
- **DRUG:** Osimertinib

## Key facts

- **NCT ID:** NCT07669779
- **Lead sponsor:** Akeso
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2026-07-10
- **Primary completion:** 2027-08-30
- **Final completion:** 2029-05-30
- **Target enrollment:** 348 (ESTIMATED)
- **Last updated:** 2026-07-14


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT07669779

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT07669779, "A Phase II Study of AK146D1 in Combination With AK112 in Advanced Non-Small Cell Lung Cancer". Retrieved via MORVS 2026-10-20 from https://api.morvs.ai/clinical/NCT07669779. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*